Celgene and Acceleron Announce New Results from an Investigational Study with Luspatercept in Beta-Thalassemia Presented at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition

Celgene and Acceleron Announce New Results from an Investigational Study with Luspatercept in Beta-Thalassemia Presented at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition

December 11, 2015

SUMMIT, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) and Acceleron Pharma Inc. (NASDAQ:XLRN) today announced preliminary results from two Phase 2 clinical trials of luspatercept in patients with beta-thalassemia were presented at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition.

Agios Pharmaceuticals, Inc.

Agios Announces Initiation of Phase 1b Frontline Trial of AG-221 or AG-120 in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients

Agios Announces Initiation of Phase 1b Frontline Trial of AG-221 or AG-120 in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients

December 18, 2015

CAMBRIDGE, Mass., Dec. 18, 2015 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals Inc., (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced the initiation of a Phase 1b, multicenter, international, open-label study of AG-221 or AG-120 in combination with induction and consolidation therapy in patients with newly diagnosed acute myeloid leukemia (AML) with an isocitrate dehydrogenase (IDH) mutation who are eligible for intensive chemotherapy.

Seres Therapeutics Announces Initiation of a Phase 1b Clinical Trial of SER-287 in Mild-to-Moderate Ulcerative Colitis

Seres Therapeutics Announces Initiation of a Phase 1b Clinical Trial of SER-287 in Mild-to-Moderate Ulcerative Colitis

December 14, 2015

CAMBRIDGE, Mass. (BUSINESS WIRE)--Dec. 14, 2015--Seres Therapeutics Inc. (NASDAQ:MCRB), a leading microbiome therapeutics company, announced today that it has initiated a Phase 1b clinical trial evaluating SER-287 in mild-to-moderate ulcerative colitis (UC). The program IND has been cleared by the FDA, and clinical investigational sites are now open and actively enrolling patients. SER-287 is the first microbiome therapeutic candidate to reach clinical-stage development in a chronic disease, and the first in an indication outside of infectious disease.

BIND Therapeutics Appoints Jonathan Yingling, Ph.D., as Chief Scientific Officer

BIND Therapeutics Appoints Jonathan Yingling, Ph.D., as Chief Scientific Officer

December 16, 2015

CAMBRIDGE, Mass.--(BUSINESS WIRE)--BIND Therapeutics, Inc. (NASDAQ:BIND), a clinical-stage nanomedicine company developing targeted and programmable therapeutics called ACCURINS(R), today announced the appointment of Jonathan Yingling, Ph.D., as Chief Scientific Officer. In this position, Dr. Yingling will be responsible for leading BIND's research and development efforts to identify and pursue new product opportunities where the unique attributes of ACCURINs can be leveraged to provide meaningful improvements in patient care.

BIND Therapeutics to Advance BIND-014 Squamous Histology Non-Small Cell Lung Cancer Cohort to Second Stage of iNSITE 1 Trial

BIND Therapeutics to Advance BIND-014 Squamous Histology Non-Small Cell Lung Cancer Cohort to Second Stage of iNSITE 1 Trial

December 14, 2015

CAMBRIDGE, Mass.--(BUSINESS WIRE)--BIND Therapeutics, Inc. (NASDAQ:BIND), a clinical-stage nanomedicine company developing targeted and programmable therapeutics called ACCURINS(R), today announced that the squamous histology non-small cell lung cancer (NSCLC) cohort of the phase 2 iNSITE 1 trial will advance to the second stage and complete enrollment to 40 patients. The company also announced that the KRAS mutant NSCLC arm will not advance to the second stage.

Dr. Elizabeth Nabel Joins Moderna Therapeutics’ Board of Directors

Dr. Elizabeth Nabel Joins Moderna Therapeutics’ Board of Directors

December 15, 2015

CAMBRIDGE, Mass., December 15, 2015 — Moderna Therapeutics, a pioneer in the development of messenger RNA (mRNA) Therapeutics (TM), announced today that Elizabeth (Betsy) Nabel, M.D., President of Harvard-affiliated Brigham and Women's Health Care (BWHC) has been appointed to the company's Board of Directors.

FDA Fast Track Designation Granted to Luspatercept for the Treatment of Patients with Lower-Risk Myelodysplastic Syndromes

FDA Fast Track Designation Granted to Luspatercept for the Treatment of Patients with Lower-Risk Myelodysplastic Syndromes

December 11, 2015

BUSINESS WIRE--Celgene Corporation (NASDAQ:CELG) and Acceleron Pharma Inc. (NASDAQ:XLRN) today announced that the United States Food and Drug Administration (FDA) has granted Fast Track Designation to luspatercept for the treatment of anemia in patients with lower-risk myelodysplastic syndromes (MDS). The Fast Track program of the FDA is designed to facilitate the development, and expedite the review, of new drugs that are intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs.

Agios Announces Data from Ongoing Phase 1/2 Trial of AG-221 Showing Durable Responses in Patients with Advanced Hematologic Malignancies

Agios Announces Data from Ongoing Phase 1/2 Trial of AG-221 Showing Durable Responses in Patients with Advanced Hematologic Malignancies

December 11, 2015

CAMBRIDGE, Mass., Dec. 6, 2015 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced new data from the dose-escalation phase and expansion cohorts from the ongoing Phase 1/2 study evaluating single agent AG-221, a first-in-class, oral, selective, potent inhibitor of mutant isocitrate dehydrogenase-2 (IDH2), in advanced hematologic malignancies.

EcoSense Lighting Acquires Journee Lighting

EcoSense Lighting Acquires Journee Lighting

December 11, 2015

LOS ANGELES, Dec. 8, 2015 /PRNewswire/ -- EcoSense®, a fast-growing LED technology company, announced today that it has acquired the assets of Journée Lighting. Journée Lighting is a privately owned, CA-based lighting company that specializes in the design and development of specification grade lighting.

Flagship Ventures Launches Rubius To Develop Red-Cell Therapeutics™

Flagship Ventures Launches Rubius To Develop Red-Cell Therapeutics™

December 9, 2015

Following 18 Months of Technology Development, Company Advances Breakthrough Therapeutic Platform with $25M of Initial Capital